β1 Integrin Inhibition Elicits a Prometastatic Switch Through the TGFβ–miR-200–ZEB Network in E-Cadherin–Positive Triple-Negative Breast Cancer

Hoa H. Truong; Jiangling Xiong; Veerander P. S. Ghotra; Ella Nirmala; Lizette Haazen; Sylvia E. Le Dévédec; Hayri E. Balcioğlu; Shuning He; B. Ewa Snaar-Jagalska; Erno Vreugdenhil; John H. N. Meerman; Bob van de Water; Erik H. J. Danen

doi:10.1126/scisignal.2004751

Research ArticleCancer

β₁ Integrin Inhibition Elicits a Prometastatic Switch Through the TGFβ–miR-200–ZEB Network in E-Cadherin–Positive Triple-Negative Breast Cancer

Hoa H. Truong¹,*,
Jiangling Xiong¹,*,
Veerander P. S. Ghotra¹,
Ella Nirmala¹,
Lizette Haazen¹,
Sylvia E. Le Dévédec¹,
Hayri E. Balcioğlu¹,
Shuning He²,
B. Ewa Snaar-Jagalska²,
Erno Vreugdenhil³,
John H. N. Meerman¹,
Bob van de Water¹, and
Erik H. J. Danen¹,†

¹Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden 2333CC, the Netherlands.
²Department of Molecular Cell Biology, Institute of Biology, Leiden University, Leiden 2333CC, the Netherlands.
³Division of Medical Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden 2333CC, the Netherlands.

↵†Corresponding author. E-mail: e.danen{at}lacdr.leidenuniv.nl

↵* These authors contributed equally to this work.

See allHide authors and affiliations

Science Signaling 11 Feb 2014:
Vol. 7, Issue 312, pp. ra15
DOI: 10.1126/scisignal.2004751

Hoa H. Truong

Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden 2333CC, the Netherlands.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jiangling Xiong

Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden 2333CC, the Netherlands.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Veerander P. S. Ghotra

Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden 2333CC, the Netherlands.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ella Nirmala

Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden 2333CC, the Netherlands.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lizette Haazen

Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden 2333CC, the Netherlands.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sylvia E. Le Dévédec

Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden 2333CC, the Netherlands.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Hayri E. Balcioğlu

Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden 2333CC, the Netherlands.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Shuning He

Department of Molecular Cell Biology, Institute of Biology, Leiden University, Leiden 2333CC, the Netherlands.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

B. Ewa Snaar-Jagalska

Department of Molecular Cell Biology, Institute of Biology, Leiden University, Leiden 2333CC, the Netherlands.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Erno Vreugdenhil

Division of Medical Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden 2333CC, the Netherlands.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

John H. N. Meerman

Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden 2333CC, the Netherlands.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Bob van de Water

Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden 2333CC, the Netherlands.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Erik H. J. Danen

Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden 2333CC, the Netherlands.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: e.danen@lacdr.leidenuniv.nl

Article
Figures & Data
Info & Metrics
eLetters
PDF

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Submit a Response to This Article

Compose eLetter

Title

Contents

More information about text formats

Plain text

Plain text
No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First name and middle name First or given name, e.g. 'Peter'. Last Name Your last, or family, name, e.g. 'MacMoody'. Email Your email address, e.g. higgs-boson@gmail.com Role / Occupation Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests?

Yes

Please describe the competing interests

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

What code is in the image? Enter the characters shown in the image.

Vertical Tabs

No eLetters have been published for this article.

View Full Text

β₁ Integrin Inhibition Elicits a Prometastatic Switch Through the TGFβ–miR-200–ZEB Network in E-Cadherin–Positive Triple-Negative Breast Cancer

Plain text

Vertical Tabs

Science Signaling

Article Tools

β₁ Integrin Inhibition Elicits a Prometastatic Switch Through the TGFβ–miR-200–ZEB Network in E-Cadherin–Positive Triple-Negative Breast Cancer

Citation Manager Formats

β₁ Integrin Inhibition Elicits a Prometastatic Switch Through the TGFβ–miR-200–ZEB Network in E-Cadherin–Positive Triple-Negative Breast Cancer

Citing Articles in:

share

Plain text

Vertical Tabs

Science Signaling

Article Tools